TLX News: Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging - 17th Oct 2022, 10:25am

[annb0t]

MELBOURNE, Australia, Oct. 17, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved an investigational new drug (IND) application to commence a pivotal Phase III registration study of TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11), for the imaging of prostate cancer using Positron Emission Tomography (PET) that will bridge to the mar...

>>> Read more: Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging